Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia K, Heales S, Sebire NJ, Zetterberg H, Mills K.

Mol Neurodegener. 2015 Dec 1;10:64. doi: 10.1186/s13024-015-0059-y. Erratum in: Mol Neurodegener. 2016;11:20. Bahtia, Kailash and Zetterburg, Henrik [Corrected to Bhatia, Kailash and Zetterberg, Henrik].

2.

Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.

da Costa G, Ribeiro-Silva C, Ribeiro R, Gilberto S, Gomes RA, Ferreira A, Mateus É, Barroso E, Coelho AV, Freire AP, Cordeiro C.

PLoS One. 2015 Jul 6;10(7):e0125392. doi: 10.1371/journal.pone.0125392. eCollection 2015.

3.

Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease.

Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, Zerbinatti C.

PLoS One. 2014 Jul 22;9(7):e103187. doi: 10.1371/journal.pone.0103187. eCollection 2014.

4.

Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing.

Bouter Y, Kacprowski T, Weissmann R, Dietrich K, Borgers H, Brauß A, Sperling C, Wirths O, Albrecht M, Jensen LR, Kuss AW, Bayer TA.

Front Aging Neurosci. 2014 Apr 16;6:75. doi: 10.3389/fnagi.2014.00075. eCollection 2014.

5.

The role of clusterin in amyloid-β-associated neurodegeneration.

Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative Group.

JAMA Neurol. 2014 Feb;71(2):180-7. doi: 10.1001/jamaneurol.2013.4560.

6.

Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration.

Asuni AA, Gray B, Bailey J, Skipp P, Perry VH, O'Connor V.

J Biol Chem. 2014 Feb 14;289(7):4532-45. doi: 10.1074/jbc.M113.502690. Epub 2013 Dec 23.

7.

The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Shafie IN, McLaughlin M, Burchmore R, Lim MA, Montague P, Johnston PE, Penderis J, Anderson TJ.

Cell Stress Chaperones. 2014 May;19(3):311-20. doi: 10.1007/s12192-013-0457-4. Epub 2013 Aug 29.

8.

Mass spectrometry quantification of clusterin in the human brain.

Chen J, Wang M, Turko IV.

Mol Neurodegener. 2012 Aug 20;7:41. doi: 10.1186/1750-1326-7-41.

9.

Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals.

Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS.

PLoS One. 2012;7(6):e34078. doi: 10.1371/journal.pone.0034078. Epub 2012 Jun 11.

10.

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K.

PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540. Epub 2011 Oct 26.

11.

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S.

Arch Gen Psychiatry. 2010 Jul;67(7):739-48. doi: 10.1001/archgenpsychiatry.2010.78.

12.

Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Galasko D, Montine TJ.

Biomark Med. 2010 Feb;4(1):27-36. doi: 10.2217/bmm.09.89. Review.

13.

Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake.

Yerbury JJ, Wilson MR.

Cell Stress Chaperones. 2010 Jan;15(1):115-21. doi: 10.1007/s12192-009-0122-0. Epub 2009 May 27.

14.

8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, Guertin S, Pribil P, Lee KH.

Proteomics. 2007 Oct;7(20):3651-60.

Items per page

Supplemental Content

Write to the Help Desk